EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Management of severe tardive dyskinesia induced by Aripiprazole in a schizophrenic patient: a case report

Farzad Fayedeh, Mahya Mojahedi, Danial Gharaie Amirabadi

Journal of Medical Case Reports · 20.07.2026 · 20 (1)

DOI: 10.1186/s13256-026-06384-2 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Medical Case Reports, online erschienen am 20.07.2026. Verfasst von Farzad Fayedeh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran. Hauptthemen laut MEDLINE: Aripiprazole, Antipsychotic Agents, Schizophrenia, Tetrabenazine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tardive dyskinesia (TD) is a disabling movement disorder induced by prolonged administration of dopamine receptor–blocking agents, primarily high-potency first-generation antipsychotics. Case presentation We report the case of a 32-year-old Iranian male patient with schizophrenia who developed TD following treatment with the second-generation antipsychotic aripiprazole. The patient experienced involuntary facial and jaw movements that started about four weeks after he abruptly discontinued the drug on his own. While there was a generally reduced risk of extrapyramidal symptoms with second-generation antipsychotics, the patient’s symptoms were clinically significant and impacted his quality of life. Initial management efforts were not beneficial; however, after adjustment of the previous antipsychotic therapy and introduction of tetrabenazine, a VMAT2 inhibitor approved for TD, the patient showed marked symptomatic improvement.

Conclusion

This case emphasizes clinical awareness of the possibility of risk for tardive dyskinesia despite atypical antipsychotics such as aripiprazole and the therapeutic value of tetrabenazine as an important treatment option for this intractable condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazoleAntipsychotic AgentsSchizophreniaTetrabenazineTardive DyskinesiaDyskinesia, Drug-InducedAdrenergic Uptake InhibitorsHumansMaleAdultTreatment OutcomeQuality of Life

Stichwörter der Autor:innen

AntipyschoitcsCase reportSGASSchizophreniaTardive dyskenisa

Substanzen

AripiprazoleAntipsychotic AgentsTetrabenazineAdrenergic Uptake Inhibitors

Autor:innen und Institutionen

  • Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.
  • Clinical Research Development Unit, Imam Reza Hospital, Birjand University of Medical Sciences, Birjand, Iran.
  • Department of Psychiatry, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran. mah.mojahedi@gmail.com.

Zitieren

APA

Fayedeh, F., Mojahedi, M., & Gharaie Amirabadi, D. (2026). Management of severe tardive dyskinesia induced by Aripiprazole in a schizophrenic patient: a case report. Journal of Medical Case Reports, 20(1). https://doi.org/10.1186/s13256-026-06384-2

Vancouver

Fayedeh F, Mojahedi M, Gharaie Amirabadi D. Management of severe tardive dyskinesia induced by Aripiprazole in a schizophrenic patient: a case report. Journal of Medical Case Reports. 2026;20(1). doi:10.1186/s13256-026-06384-2

BibTeX
@article{Fayedeh2026,
  author = {Fayedeh, Farzad and Mojahedi, Mahya and Gharaie Amirabadi, Danial},
  title = {Management of severe tardive dyskinesia induced by Aripiprazole in a schizophrenic patient: a case report},
  journal = {Journal of Medical Case Reports},
  year = {2026},
  volume = {20},
  number = {1},
  doi = {10.1186/s13256-026-06384-2}
}
Kostenlos starten →